Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Restless legs syndrome in multiple sclerosis.
Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study.
Studies in Experimental Autoimmune Encephalomyelitis Do Not Support Developmental Bisphenol A Exposure as an Environmental Factor in Increasing Multiple Sclerosis Risk.
IL-25 prevents T cell-mediated neurotoxicity by decreasing LFA-1 expression.
Laquinimod in the treatment of multiple sclerosis: a review of the data so far.
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.
Cytokines and chemokines in multiple sclerosis.
Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis.
Pushing the boundaries of neuromyelitis optica: Does antibody make the disease?
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis.
G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration.
[Adaptative immunity and pathophysiology of multiple sclerosis.]
Sexual problems among women with multiple sclerosis.
What are exosomes and how can they be used in multiple sclerosis therapy?
Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis.
Heat shock proteins and hormesis in the diagnosis and treatment of neurodegenerative diseases.
The mechanisms of neurotoxicity and the selective vulnerability of nervous system sites.
Progressive MS: from pathophysiology to drug discovery.
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
Pregnancy Does Not Prove Neuroprotective for Women with MS Who Stop Taking Natalizumab
Frontrunners of T cell activation: Initial, localized Ca2+ signals mediated by NAADP and the type 1 ryanodine receptor.
Fatigue, Sleep Quality, and Disability in Relation to Quality of Life in Multiple Sclerosis.
White and gray matter damage in primary progressive MS: The chicken or the egg?
Toward the identification of neuroprotective agents: g-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist.

Pages